# Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

> **NCT06679816** · PHASE4 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 882 (estimated)

## Conditions studied

- Pituitary Adenoma
- Pituitary Neuroendocrine Tumor

## Interventions

- **DRUG:** Hormone replacement therapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06679816
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 882 (ESTIMATED)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679816, "Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06679816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*